{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:10:14Z","timestamp":1783570214758,"version":"3.55.0"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62072172"],"award-info":[{"award-number":["62072172"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["61803151"],"award-info":[{"award-number":["61803151"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Coronavirus disease 2019 (COVID-19) is rapidly spreading. Researchers around the world are dedicated to finding the treatment clues for COVID-19. Drug repositioning, as a rapid and cost-effective way for finding therapeutic options from available FDA-approved drugs, has been applied to drug discovery for COVID-19. In this study, we develop a novel drug repositioning method (VDA-KLMF) to prioritize possible anti-SARS-CoV-2 drugs integrating virus sequences, drug chemical structures, known Virus-Drug Associations, and Logistic Matrix Factorization with Kernel diffusion. First, Gaussian kernels of viruses and drugs are built based on known VDAs and nearest neighbors. Second, sequence similarity kernel of viruses and chemical structure similarity kernel of drugs are constructed based on biological features and an identity matrix. Third, Gaussian kernel and similarity kernel are diffused. Forth, a logistic matrix factorization model with kernel diffusion is proposed to identify potential anti-SARS-CoV-2 drugs. Finally, molecular dockings between the inferred antiviral drugs and the junction of SARS-CoV-2 spike protein-ACE2 interface are implemented to investigate the binding abilities between them. VDA-KLMF is compared with two state-of-the-art VDA prediction models (VDA-KATZ and VDA-RWR) and three classical association prediction methods (NGRHMDA, LRLSHMDA, and NRLMF) based on 5-fold cross validations on viruses, drugs, and VDAs on three datasets. It obtains the best recalls, AUCs, and AUPRs, significantly outperforming other five methods under the three different cross validations. We observe that four chemical agents coming together on any two datasets, that is, remdesivir, ribavirin, nitazoxanide, and emetine, may be the clues of treatment for COVID-19. The docking results suggest that the key residues K353 and G496 may affect the binding energies and dynamics between the inferred anti-SARS-CoV-2 chemical agents and the junction of the spike protein-ACE2 interface. Integrating various biological data, Gaussian kernel, similarity kernel, and logistic matrix factorization with kernel diffusion, this work demonstrates that a few chemical agents may assist in drug discovery for COVID-19.<\/jats:p>","DOI":"10.3389\/fmicb.2022.740382","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T07:52:15Z","timestamp":1646034735000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Discovery of Potential Therapeutic Drugs for COVID-19 Through Logistic Matrix Factorization With Kernel Diffusion"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiongfei","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,28]]},"reference":[{"key":"B1","year":"2017","journal-title":"HCV Guidance."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1016\/S0140-6736(20)31303-9","article-title":"Men\u2019s health: COVID-19 pandemic highlights need for overdue policy action.","volume":"395","author":"Baker","year":"2020","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaa205","article-title":"DTI-MLCD: predicting drug-target interactions using multi-label learning with community detection method.","volume":"22","author":"Chu","year":"2020","journal-title":"Br. Bioinform."},{"key":"B4","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1093\/bib\/bbaa288","article-title":"A review on drug repurposing applicable to COVID-19.","volume":"22","author":"Dotolo","year":"2020","journal-title":"Br. Bioinform."},{"key":"B5","first-page":"2121","article-title":"Adaptive subgradient methods for online learning and stochastic optimization.","volume":"12","author":"Duchi","year":"2011","journal-title":"J. Mach. Learn. Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","article-title":"Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19.","volume":"6","author":"Eastman","year":"2020","journal-title":"ACS Central Sci."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117477","article-title":"Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.","volume":"248","author":"Elfiky","year":"2020","journal-title":"Life Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1080\/07391102.2020.1758791","article-title":"Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes.","volume":"39","author":"Elmezayen","year":"2020","journal-title":"J. Biomol. Struct. Dyna."},{"key":"B9","year":"2021"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1008686","article-title":"SAveRUNNER: a network-based algorithm for drug repurposing and its application to COVID-19.","volume":"17","author":"Fiscon","year":"2021","journal-title":"PLoS Comput. Biol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.aca.2016.01.014","article-title":"Improved prediction of drug-target interactions using regularized least squares integrating with kernel fusion technique.","volume":"909","author":"Hao","year":"2016","journal-title":"Anal. Chim. Acta"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1001\/jama.2020.4169","article-title":"Managing COVID-19 in low-and middle-income countries.","volume":"323","author":"Hopman","year":"2020","journal-title":"JAMA"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-017-1304-7","article-title":"Prediction of microbe-disease association from the integration of neighbor and graph with collaborative recommendation model.","volume":"15","author":"Huang","year":"2017","journal-title":"J. Trans. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1080\/07391102.2020.1761883","article-title":"A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2.","volume":"39","author":"Islam","year":"2021","journal-title":"J. Biomol. Struct. Dyna."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2020.1784291","article-title":"Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.","volume":"2020","author":"Kandeel","year":"2020","journal-title":"J. Biomol. Struct. Dyna."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1093\/bib\/bbx108","article-title":"MAFFT online service: multiple sequence alignment, interactive sequence choice and visualization.","volume":"20","author":"Katoh","year":"2019","journal-title":"Br. Bioinform."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1016\/j.csbj.2020.08.006","article-title":"Structural insights into the mechanism of RNA recognition by the N-terminal RNA-binding domain of the SARS-CoV-2 nucleocapsid phosphoprotein.","volume":"18","author":"Khan","year":"","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s12539-020-00381-9","article-title":"Phylogenetic analysis and structural perspectives of RNA-dependent RNA-polymerase inhibition from SARs-CoV-2 with natural products.","volume":"12","author":"Khan","year":"","journal-title":"Interdisciplinary Sci. Comput. Life Sci."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.202100191","article-title":"Preliminary structural data revealed that the SARS-CoV-2 B. 1.617 Variant\u2019s RBD binds to ACE2 receptor stronger than the wild type to enhance the infectivity.","volume":"22","author":"Khan","year":"2021","journal-title":"ChemBioChem"},{"key":"B21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000513686","article-title":"Structures of SARS-CoV-2 RNA-binding proteins and therapeutic targets.","volume":"64","author":"Khan","year":"2021","journal-title":"Intervirology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2021.1882337","article-title":"Targeting the N-terminal domain of the RNA-binding protein of the SARS-CoV-2 with high affinity natural compounds to abrogate the protein-RNA interaction: a molecular dynamics study.","volume":"2021","author":"Khan","year":"2021","journal-title":"J. Biomol. Struct. Dyna."},{"key":"B23","author":"Landrum","year":"2021","journal-title":"RDKit: Open-Source Cheminformatics Software."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2021.100116","article-title":"Genomic variation, origin tracing, and vaccine development of SARS-CoV-2: A systematic review.","volume":"2","author":"Li","year":"2021","journal-title":"Innovation"},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.1016\/j.knosys.2019.105261","article-title":"Predicting lncRNA\u2013miRNA interactions based on logistic matrix factorization with neighborhood regularized.","volume":"191","author":"Liu","year":"2020","journal-title":"Know. Based Syst."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/srep22811","article-title":"A systematic study on drug-response associated genes using baseline gene expressions of the cancer cell line encyclopedia.","volume":"6","author":"Liu","year":"2016","journal-title":"Sci. Rep."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004760","article-title":"Neighborhood regularized logistic matrix factorization for drug-target interaction prediction.","volume":"12","author":"Liu","year":"2016","journal-title":"PLoS Comput. Biol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s40200-020-00546-9","article-title":"Drug repurposing using computational methods to identify therapeutic options for COVID-19.","volume":"19","author":"Mahdian","year":"2020","journal-title":"J. Diab. Metab. Dis."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00162-20","article-title":"Remdesivir against COVID-19 and other viral diseases.","volume":"34","author":"Malin","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.34172\/bi.2020.25","article-title":"Computational-based drug repurposing methods in COVID-19.","volume":"10","author":"Masoudi-Sobhanzadeh","year":"2020","journal-title":"BioImpacts"},{"key":"B31","first-page":"845","article-title":"The performance of current methods in ligand-protein docking.","volume":"83","author":"McConkey","year":"2002","journal-title":"Curr. Sci."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.asoc.2021.107135","article-title":"Drug repositioning based on similarity constrained probabilistic matrix factorization: COVID-19 as a case study.","volume":"103","author":"Meng","year":"2021","journal-title":"Appl. Soft Comput."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02405-w","article-title":"COVID-19: viral-host interactome analyzed by network based-approach model to study pathogenesis of SARS-CoV-2 infection.","volume":"18","author":"Messina","year":"2020","journal-title":"J. Transl. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility.","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1080\/07391102.2020.1752802","article-title":"Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 Protease against COVID-19.","volume":"39","author":"Muralidharan","year":"2020","journal-title":"J. Biomol. Struct. Dyna."},{"key":"B36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3969\/j.issn.1001-5256.2015.04.003","article-title":"An update on the management of chronic hepatitis C: 2015 consensus guidelines from the canadian association for the study of the liver.","volume":"29","author":"Myers","year":"2015","journal-title":"Can. J. Gastroent. Hepatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-83737-5","article-title":"Prioritizing antiviral drugs against SARS-CoV-2 by integrating viral complete genome sequences and drug chemical structures.","volume":"11","author":"Peng","year":"2021","journal-title":"Sci. Rep."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.577387","article-title":"Identifying effective antiviral drugs against SARS-CoV-2 by drug repositioning through virus-drug association prediction.","volume":"11","author":"Peng","year":"2020","journal-title":"Front. Genet."},{"key":"B39","doi-asserted-by":"publisher","first-page":"D271","DOI":"10.1093\/nar\/gkw1000","article-title":"The RCSB protein data bank: integrative view of protein, gene and 3D structural information.","volume":"45","author":"Rose","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17189-2","article-title":"Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing.","volume":"11","author":"Sadegh","year":"2020","journal-title":"Nat. Commun."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12038-020-00067-w","article-title":"Drug targets for COVID-19 therapeutics: ongoing global efforts.","volume":"45","author":"Saxena","year":"2020","journal-title":"J. Biosci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"D92","DOI":"10.1093\/nar\/gkaa1023","article-title":"GenBank.","volume":"49","author":"Sayers","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"B43","article-title":"The PyMOL molecular graphics system.","volume":"1","author":"Schrodinger","year":"2010","journal-title":"Version"},{"key":"B44","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2174\/1570163814666170727130003","article-title":"Update on nitazoxanide: a multifunctional chemotherapeutic agent.","volume":"15","author":"Shakya","year":"2017","journal-title":"Curr. Drug Discov. Technol."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2021.105119","article-title":"VDA-RWLRLS: an anti-SARS-CoV-2 drug prioritizing framework combining an unbalanced bi-random walk and Laplacian regularized least squares.","volume":"140","author":"Shen","year":"2022","journal-title":"Comput. Biol. Med."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.603615","article-title":"Indicator regularized non-negative matrix factorization method-based drug repurposing for COVID-19.","volume":"11","author":"Tang","year":"2020","journal-title":"Front. Immunol."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.05.015","article-title":"Human intestinal defensin 5 inhibits SARS-CoV-2 invasion by cloaking ACE2.","volume":"159","author":"Wang","year":"2020","journal-title":"Gastroenterology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1021\/acsinfecdis.1c00096","article-title":"Human cathelicidin inhibits SARS-CoV-2 infection: killing two birds with one stone.","volume":"7","author":"Wang","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-08127-2","article-title":"LRLSHMDA: laplacian regularized least squares for human microbe-disease association prediction.","volume":"7","author":"Wang","year":"2017","journal-title":"Sci. Rep."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.749256","article-title":"Screening potential drugs for COVID-19 based on bound nuclear norm regularization.","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Genet."},{"key":"B51","year":"2021"},{"key":"B52","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018.","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods.","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/srep32566","article-title":"Discover the network underlying the connections between aging and age-related diseases.","volume":"6","author":"Yang","year":"2016","journal-title":"Sci. Rep."},{"key":"B55","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s11357-019-00106-x","article-title":"Human geroprotector discovery by targeting the converging subnetworks of aging and age-related diseases.","volume":"42","author":"Yang","year":"2020","journal-title":"Geroscience"},{"key":"B56","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s12539-021-00458-z","article-title":"Using network distance analysis to predict lncRNA-miRNA interactions.","volume":"13","author":"Zhang","year":"2021","journal-title":"Interdiscip. Sci."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2019","article-title":"SPVec: a Word2vec-inspired feature representation method for drug-target interaction prediction.","volume":"7","author":"Zhang","year":"2020","journal-title":"Front. Chem."},{"key":"B58","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1016\/j.ygeno.2020.07.044","article-title":"Probing antiviral drugs against SARS-CoV-2 through virus-drug association prediction based on the KATZ method.","volume":"112","author":"Zhou","year":"2020","journal-title":"Genomic"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2022.740382\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T07:52:24Z","timestamp":1646034744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2022.740382\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":58,"alternative-id":["10.3389\/fmicb.2022.740382"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2022.740382","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,28]]},"article-number":"740382"}}